Helicobacter pylori (H. pylori ) eradication is considered a necessary step in the management of peptic ulcer disease, chronic gastritis, gastric adenocarcinoma and mucosa associated lymphoid tissue lymphoma. Standard triple therapy eradication regimens are inconvenient and achieve unpredictable and often poor results. Eradication rates are decreasing over time with increase in antibiotic resistance. Fermented milk and several of its component whey proteins have emerged as candidates for complementary therapy. In this context the current review seeks to summarize the current evidence available on their role in H. pylori eradication. Pertinent narrative/systematic reviews, clinical trials and laboratory studies on individual components including fermented milk, yogurt, whey proteins, lactoferrin, α-lactalbumin (α-LA), glycomacropeptide and immunoglobulin were comprehensively searched and retrieved from Medline, Embase, Scopus, Cochrane Controlled Trials Register and abstracts/proceedings of conferences up to May 2013. A preponderance of the evidence available on fermented milk-based probiotic preparations and bovine lactoferrin suggests a beneficial effect in Helicobacter eradication. Evidence for α-LA and immunoglobulins is promising while that for glycomacropeptide is preliminary and requires substantiation. The magnitude of the potential benefit documented so far is small and the precise clinical settings are ill defined. This restricts the potential use of this group as a complementary therapy in a nutraceutical setting hinging on better patient acceptability/ compliance. Further work is necessary to identify the optimal substrate, fermentation process, dose and the ideal clinical setting (prevention/treatment, first line therapy/recurrence, symptomatic/asymptomatic, gastritis/ulcer diseases etc. ). The potential of this group in high antibiotic resistance or treatment failure settings presents interesting possibilities and deserves further exploration.
INTRODUCTION
Helicobacter pylori (H. pylori) is a gram negative, spiral shaped bacterium found in the gastric mucous layer. It has an ammonia-producing surface urease which allows adherence to and colonization of the gastric epithelium, by neutralizing the acidic gastric environment [1] . H. pylori is now implicated in peptic ulcer disease, chronic gastritis, gastric adenocarcinoma, mucosa associated lymphoid tissue lymphoma and duodenal ulcer disease [2] [3] [4] . Eradication of H. pylori is considered a necessary step in the management of these diseases. Standard triple therapy eradication regimens (proton pump inhibitor plus clarithromycin and amoxicillin or nitroimidazole) are inconvenient and achieve unpredictable and often poor results [5] . Further, eradication rates are reported to be decreasing over time with an increase in antibiotic resistance [6] . Second line quadruple regimens are further limited by poorer patient compliance and increased side effects [6] . In this context, several alternative and complementary therapies have been tried in an attempt to achieve better eradication without affecting compliance. In this search, fermented milk and several of its component whey proteins have emerged as potential candidates for complementary therapy. They have the inherent advantage of better patient acceptability.
Several randomized controlled trials and a recent meta-analysis document that fermented milk-based probiotic preparations improve H. pylori eradication rates by 10%. Their efficacy has been argued to be better than capsule-based bacteria-only preparations and considered partly or completely contributed by the anti-bacterial and immunogenic properties of component whey proteins formed as a result of fermentation etc. Potential efficacy of individual whey proteins in H. pylori eradication has also been a subject of interest in recent research. However the role of fermented milk or whey proteins in clinical practice is not yet universally accepted, precisely defined or widely discussed [7] . In this context the current review sought to summarize the current evidence available on the role of fermented milk and its component whey proteins in H. pylori eradication.
For the purpose of the current review pertinent narrative/systematic reviews, clinical trials and laboratory studies on individual components including fermented milk, yogurt, whey proteins, lactoferrin, α-lactalbumin (α-LA), glycomacropeptide and immunoglobulin were comprehensively searched and retrieved from Medline, Embase, Scopus, Cochrane Controlled Trials Register and abstracts/proceedings of conferences up to May 2013. The available studies/meta-analysis were rated for quality as per the Scottish Intercollegiate Guidelines Network (SIGN) check lists [8] and the Quality Rating for Individual Studies [9] . The evidence was subsequently graded using the Revised Grading System [10] . The level of recommendation was later defined into one of four grades (A, B, C or D; SIGN grades) [11] .
FeRmeNTeD mIlk
Fer mented milk refers to whole or skimmed milk curdled to a beverage or custard like consistency by lactic acid producing bacteria. A wide assortment of products, varying by the process, bacteria, duration and other variables, are available and widely consumed in different countries. However, there are several commonalities. Fermented milk possesses a protein system constituted by two major families of proteins i.e., casein and whey proteins. Casein is insoluble, and accounts for 80% of the whole protein inventory. Whey proteins are globular water soluble molecules and include bovine lactoferrin, α-LA, glycomacropeptide, immunoglobulin, β-lactoglobulin and lactoperoxidase. Whey is thought to have the ability to act as an antioxidant, immune enhancer, antihypertensive, antitumor, hypolipidemic, antiviral, antibacterial and as a chelating agent [12] .
In the context of Helicobacter eradication there is a fair body of evidence from trials conducted using fermented milk (usual culturally/commercially available preparations including yogurt), fermented milk based probiotic preparations (FMPPs; fermented milk with specifically added live probiotic bacteria like Lactobacilli) and capsule based probiotics. An observational study on 464 healthy Mexican subjects documented lower prevalence of H. pylori seropositivity in those consuming yogurt more than once a week compared with nonconsumers [13] . As presented in Table 1 , several clinical trials and a systematic review of RCTs compared an FMPP vs placebo or standard therapy plus FMPP vs standard therapy and documented a beneficial effect of FMPPs [14] . The overall quality and quantity of evidence for FMPPs appears convincing (Recommendation Grade-A) and beneficial effect appears to be sustained when FMPP were used in combination with standard therapy (Recommendation Grade A [15] [16] [17] [18] ). Also, benefit has been documented in symptomatic children (Recommendation Grade-B), symptomatic and asymptomatic adults (Recommendation Grade-B) and in patients who failed eradication on standard therapy (Recommendation Grade-B). The overall magnitude of the benefit was estimated to be 5%-15% [14] .
With reference to the active principle components responsible for this effect, the available clinical evidence can be better summarized on the basis of three argu- [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Secondly, capsule based probiotic preparations (bacteria only) should be partly or completely ineffective in H. pylori eradication [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] . Thirdly, if FMPP's are compared with a fermented milk control group then in the control group there should be some improvement partly or completely negating the effect of the addition of bacteria in the treatment group [39] [40] [41] .
As summarized in Tables 1-3, the available evidence supports the above assertions and arguments. It is evident from the clinical studies and meta-analysis presented in Tables 1-3 that FMPPs have some efficacy against Helicobacter (10 positive trials and one positive meta-anal-727 January 21, 2014|Volume 20|Issue 3| WJG|www.wjgnet.com Cats et al [22] Levels of evidence: 1++ High quality meta-analysis, systematic reviews of RCTs, or RCTs with a very low risk of bias; 1+ Well conducted meta-analysis, systematic reviews of RCTs or RCTs with a low risk of bias; 1-Meta-analysis, systematic reviews or RCTs or RCTs with a high risk of bias; 2++ High quality systematic reviews of case-control or cohort studies or high quality case-control or cohort studies with a very low risk of confounding, bias, or chance and a high probability that the relationship is causal; 2+ Well conducted case control or cohort studies with a low risk of confounding, bias, or chance and a significant risk that the relationship is not causal; 3 Non-analytic studies, e.g., case reports, case series; 4 Expert opinion. 2 Quality rating for individual studies: ++ Applies if all or most criteria from the checklist are fulfilled; where criteria are not fulfilled the conclusions of the study or review are thought very unlikely to alter; + Applies if some of the criteria from the checklist are fulfilled; where criteria are not fulfilled or are not adequately described, the conclusions of the study or review are thought unlikely to alter; -Applies if few or no criteria from the checklist are fulfilled; where criteria are not fulfilled or are not adequately described, the conclusions of the study or review are thought likely or very likely to alter. H. pylori: Helicobacter pylori; RCT: Randomised controlled trial; CCT: Controlled clinical trial; CT: Clinical trial; C-UBT: 13 Cremonini et al [36] , Tursi et al [37] Levels of evidence: 1++ High quality meta-analysis, systematic reviews of RCTs, or RCTs with a very low risk of bias; 1+ Well conducted meta-analysis, systematic reviews of RCTs or RCTs with a low risk of bias; 1-Meta-analysis, systematic reviews or RCTs or RCTs with a high risk of bias; 2++ High quality systematic reviews of case-control or cohort studies or high quality case-control or cohort studies with a very low risk of confounding, bias, or chance and a high probability that the relationship is causal; 2+ Well conducted case control or cohort studoes with a low risk of confounding, bias, or chance and a significant risk that the relationship is not causal; 3 Non-analytic studies, e.g., case reports, case series; 4 Expert opinion. 2 preparations in Helicobacter eradication can, at best, be classified as "equivocal" (3 trials with weak methodology and equivocal results). This apprehension is further substantiated by a meta-analytic sub-analysis presented in an earlier report [42] . In this sub-analysis the beneficial effect of these preparations was minimal and it failed on exclusion sensitivity analysis (exclusion of one study majorly altered results) in consonance with the hypothesized argument.
In the context of studies comparing FMPP with fer-mented milk, several results are noteworthy. Of the three trials reporting control group data, two (one RCT and one CCT; Evidence grade 1-) [39, 40] documented an improvement in gastritis or C-UBT values in the control group which is consistent with the argument presented earlier. In the third pre-and post-intervention trial (clinical trial, evidence grade 2 [41] ) no significant differences were observed during the period that yogurt was administered alone. Hence, although there are some discrepant results the preponderance of the available evidence appears con- There was no significant difference in C-UBT levels at 0 (26.2 ± 15.1) and 9 (26.6 ± 13.7) wk 1 Levels of evidence: 1++ High quality meta-analysis, systematic reviews of RCTs, or RCTs with a very low risk of bias; 1+ Well conducted meta-analysis, systematic reviews of RCTs or RCTs with a low risk of bias; 1-Meta-analysis, systematic reviews or RCTs or RCTs with a high risk of bias; 2++ High quality systematic reviews of case-control or cohort studies or high quality case-control or cohort studies with a very low risk of confounding, bias, or chance and a high probability that the relationship is causal; 2+ Well conducted case control or cohort studoes with a low risk of confounding, bias, or chance and a significant risk that the relationship is not causal; 3 Non-analytic studies, e.g., case reports, case series; 4 Expert opinion. 2 Quality rating for individual studies: ++ Applies if all or most criteria from the checklist are fulfilled; where criteria are not fulfilled the conclusions of the study or review are thought very unlikely to alter; + Applies if some of the criteria from the checklist are fulfilled; where criteria are not fulfilled or are not adequately described, the conclusions of the study or review are thought unlikely to alter; -Applies if few or no criteria from the checklist are fulfilled; where criteria are not fulfilled or are not adequately described, the conclusions of the study or review are thought likely or very likely to alter. H. pylori: Helicobacter pylori; RCT: Randomised controlled trial; CCT: Controlled clinical trial; CT: Clinical trial; C-UBT: 13 C-urea breath test.
Table 4 Whey protein components and its basic properties
sistent with the hypothesis that whey milk proteins may partly or completely explain the anti-Helicobacter properties of fermented milk based probiotic preparations.
Overall, the recommendation for fermented milk may be classified as Recommendation Grade-A. The magnitude of the benefit achieved by FMPPs is small (10%) but holds across a variety of preparations. FMPPs also carry the potential inherent advantage of better patient acceptability. Thus, they could offer a viable alternative for complementing traditional regimens. Further research is necessary to identify the active substrate/s and to define the exact product to be used, the optimal clinical setting (prevention/treatment, first line therapy/ recurrence, symptomatic/asymptomatic, gastritis/ulcer diseases, treatment failure etc.) and potential benefits in the setting of high antibiotic resistance.
Whey PROTeINs
Whey proteins are globular water soluble molecules constituting 20% of the milk protein system. The whey protein profile, including general chemical, physicochemical and biological properties is depicted in Table 4 . β-LG comprises the maximum percentage of whey protein but it has not been documented to possess any anti-bacterial properties. Other proteins have promising antibacterial Grades of recommendations: A: At least one meta-analysis, systematic review, or RCT rated as 1++ and directly applicable to the target population or A systematic review of RCTs or a body of evidence consisting principally of studies rated as 1++ directly applicable to the target population and demonstrating overall consistency of results; B: A body of evidence including studies rated as 2++ directly applicable to the target population and demonstrating overall consistency of results or Extrapolated evidence from studies rated as 1++ or 1+; C: A body of evidence including studies rated as 2+ directly applicable to the target population and demonstrating overall consistency of results or Extrapolated evidence from studies rated as 2++; D: Evidence level 3 or 4 or Extrapolated evidence from studies rated as 2+.
attributes and hence have been studied in in vitro, in vivo and in human trials. With specific reference to H. pylori infection and associated conditions lactoferrin, α-LA, glycomacropeptide and immunoglobulins appear to be potentially relevant and warrant further discussion.
Bovine lactoferrin
Bovine lactoferrin, an iron-binding glycoprotein, is a non-enzymatic antioxidant found in the whey fraction of fermented milk as well as in colostrum. The possibility that bLF may help to improve the H. pylori eradication rate was first conceived in 1997 when, in an in vitro study by Yamazaki et al [43] , bLf was found to be bactericidal to H. pylori in Brucella broth. Later in vitro studies have confirmed the same and yielded evidence of the possible mechanism of bactericidal action of bLf relating it to the high iron-binding affinity and prevention of iron utilization by H. pylori [44, 45] . An additional mechanism based on the interaction of bLf with the bacterial surface is also suggested in the context of bactericidal effect on S. mutans and V. cholerae [46] . It has been observed that bLf can bind to the outer membrane of Gram-negative bacteria and trigger the release of lipopolysaccharides, and kill the bacteria through osmotic damage [47, 48] . Building on the available evidence Wada et al [49] , in their study, examined the therapeutic effect of bLf on H. pylori infection using in vitro and in vivo experimental systems. In the experiment a significant inhibition of H. pylori binding to gastric epithelium was accomplished within 8 h after incubation. As a follow up experiment mice infected with H. pylori were given 10 mg of bLf orally every day and their stomachs were removed after 2 wk. 40.0% of all H. pylori attached themselves to the epithelium in the stomach of the untreated mice, whereas only 19.9% of the H. pylori did in the bLf-treated mice. However, in a similar experiment by Huynh et al [50] , bLF, desferrioxamine and human recombinant lactoferrin had positive in vitro effects but all three failed to reduce H. pylori load in mice. The above experimental evidence led to several human clinical trials. These are summarized in Table 5 [43, [51] [52] [53] [54] [55] [56] [57] . As presented, 5 (of 7 available) positive clinical trials and a meta-analysis appear to establish the beneficial effect of bLf (4%-17% as per meta-analysis) on H. pylori eradication fairly well [58] . The positive response was variously explained by the authors: (1) synergistic action of the antibiotics with bLf against H. pylori; (2) Inhibition of Helicobacter growth in an acidic pH by bLf; (3) Ability of bLf to bind to iron inhibiting growth of H. pylori; and (4) decrease in incidence of side effects and non-compliance. Two studies by Zullo et al [56] and Imoto et al [57] did not show any significant difference on addition of lactoferrin to triple therapy. In the first study this could be explained by the lack of synergism between lactoferrin and amoxicillin [56] . Alternatively, the anti-bacterial effect of lactoferrin based on bacterial membrane damage of Gram negative bacteria could be marginalized when amoxicillin is administered. In the second study the authors using quadruple therapy (rabeprazole, clarithro-mycin, tinidazole and lactoferrin) showed a statistically insignificant improvement in the eradication rate (4% in ITT analysis and 7% in per-protocol analysis). The results of this trial are limited by marked geographical heterogeneity (multicentre trial) in eradication rates.
Although the available evidence suggests that bLf is beneficial (Recommendation Grade-A), the magnitude of the documented benefit is small. Given that it lacks the inherent advantage in patient acceptability (requires to be given as a drug), the concept that fermented milk potentially has a clinically significant benefit (other than suggesting that whey protein may be partly/completely responsible for the benefit with FMPP) remains unclear. Its role in various clinical settings and more so in the presence of high antibiotic resistance deserves further exploration.
α-LA α-LA is a major milk protein comprising 20-25% of whey proteins and has strong calcium binding ability. α-LA is reported to be biologically active in vivo with well-demonstrated antiulcer activity in rats. Matsumoto et al [59] , in an in vivo study using ethanol ulcer model rats, documented 82% reduction of ulcerative lesion index using 200 mg/kg bw of α-LA. Similar results were reported by Mezzaroba et al [60] , with absolute alcohol and indomethacin ulcer model rats given commercial α-LA. This intervention resulted in 30%-70% reduction in the ulcerative lesion index in comparison with controls. The exact mechanism of the protective effect and its impact on Helicobacter is not well studied. However, as reported, whey protein concentrates have consistently shown anti-Helicobacter properties. The minimal evidence on the subject precludes any definitive comment on the potential of α-LA as an anti-Helicobacter agent. The paucity of literature on the subject presents wide scope for future research.
Glycomacropeptide
Glycomacropeptide (GMP), also referred to as caseinomacropeptide and caseinoglycopeptide, is formed when bovine κ-casein is hydrolysed into para-κ-casein, which remains with the curd, and GMP, which is removed with the whey. It constitutes 15%-20% of whey protein. GMP has also been found to have several immunomodulatory functions and antibacterial properties. Otani et al [61] demonstrated that GMP, which contains sialic acid, inhibits the activity of Salmonella typhimurium lipopolysaccharide, inhibiting bacterial and viral adhesion especially to epithelial cells and dental plaque [62, 63] . Other relevant properties like suppression of gastric secretions in dogs have been reported by a study group [64] .
A study done in Japan attempted to enhance the ability of glycopeptides to bind pathogenic bacteria in vivo by conjugating with the non-digestible saccharides. The results of this study suggest that GMP could be a promising agent for preventing intestinal infection using its ability to bind pathogenic bacteria [65] . In the context 
Results and conclusion
Sachdeva et al [58] The pooled odds ratio (5-studies) for eradication by intention to treat analysis was 2.22 (95%CI: 1. 44-3.44 ; P = 0.0003) using the fixed effects model (FEM) and 2.24 (95%CI: 1. 15-4.35 ; P = 0.0003) using the random effects model (REM) (Cochran's Q = 6.83; P = 0.145). The pooled risk difference was 0.11 (95%CI: 0.05 -0.16; P = 0.0001) by FEM (Cochran's Q = 6.67; P = 0.154) and 0.10 (95%CI: 0.04-0.17; P = 0.0023) by REM. There was no significant difference in incidence of adverse effects Di Mario et al [51] of Helicobacter infection several authors have expressed the view that GMP has gastroprotective properties [66] but there is no direct evidence supporting its role in its eradication. Currently, in the absence of direct evidence the potential benefit of GMP in the treatment of H. pylori infection remains speculative.
Immunoglobulins
Immunoglobulins constitute a complex group, the elements of which are produced by B-lymphocytes. They make a significant contribution to the whey protein content (10-15%). Some of them attach to surfaces, where they behave as receptors, whereas others function as antibodies, which are released in the blood and lymph. Early et al [67] , in an in vitro study, demonstrated that whey protein concentrates produced using milk from H. pylori immunized cows contain antibodies that are active at the pH of the stomach, and bactericidal against H. pylori in vitro. Oona et al [68] , in their study on 20 children suffering from recurrent abdominal pain and with proven H. pylori infection, showed alleviation of gastritis and/or a decrease in the degree of colonization of the antrum mucosa in 9/14 children, and of the corpus mucosa in 7/15 children using immune colostrum of cows immunized (whole-cell vaccine prepared with H. pylori strain NCTC 11637) before calving. It is clear that evidence on the in vivo effects of the immunoglobulin in prevention or treatment of H. pylori infections in humans is only suggestive and deserves further work.
CONClUsION
In conclusion, FMPP and bovine lactoferrin appear to be beneficial in Helicobacter eradication (Evidence Grade-A or -B in various settings with level 1++ studies available). Evidence for α-lactabumin and whey protein concentrates enriched in immunoglobulins is "suggestive of benefit". However the studies are small and/or based on animals (level 3 or 4 studies only; no grading possible). Literature on glycomacropeptide is very preliminary precluding relevant inferences. No studies directly comparing the efficacy of individual components amongst themselves or to FMPP were available. Overall, the magnitude of the potential benefit documented so far for the group is small and the precise clinical settings are poorly defined. This restricts more widespread use of this group as a complementary therapy in a nutraceutical setting hinging on better patient acceptability/compliance. Further work is necessary to identify the optimal substrate, fermentation process, dose of administration and the ideal clinical setting (prevention/treatment, first line therapy/recurrence, symptomatic/asymptomatic, gastri-734 January 21, 2014|Volume 20|Issue 3| WJG|www.wjgnet.com Zullo et al [55] 
Effect of bLf against H. pylori
The C-UBT values at week 8 were significantly lower than those at week 0 in the bLf group (P < 0.01), whereas no difference was observed in the control group 1 Levels of evidence: 1++ High quality meta-analysis, systematic reviews of RCTs, or RCTs with a very low risk of bias; 1+ Well conducted meta-analysis, systematic reviews of RCTs or RCTs with a low risk of bias; 1-Meta-analysis, systematic reviews or RCTs or RCTs with a high risk of bias; 2++ High quality systematic reviews of case-control or cohort studies or High quality case-control or cohort studies with a very low risk of confounding, bias, or chance and a high probability that the relationship is causal; 2+ well conducted case control or cohort studoes with a low risk of confounding, bias, or chance and a significant risk that the relationship is not causal; 3 Non-analytic studies, eg case reports, case series; 4 Expert opinion. 2 Quality rating for individual studies: ++ Applies if all or most criteria from the checklist are fulfilled; where criteria are not fulfilled the conclusions of the study or review are thought very unlikely to alter; + Applies if some of the criteria from the checklist are fulfilled; where criteria are not fulfilled or are not adequately described, the conclusions of the study or review are thought unlikely to alter; -Applies if few or no criteria from the checklist are fulfilled; where criteria are not fulfilled or are not adequately described, the conclusions of the study or review are thought likely or very likely to alter. H. pylori: Helicobacter pylori; RCT: Randomised controlled trial; CCT: Controlled clinical trial; CT: Clinical trial; C-UBT: 13 C-urea breath test; FTNA: Full text not available; NS: Not significant.
tis/ulcer diseases etc.). The potential of this group in high antibiotic resistance or treatment failure settings presents interesting possibilities and deserves further exploration.
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